Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
MASLD and MASH can lead to liver fibrosis, cirrhosis and liver cancer.
Study findings suggest people with chronic liver disease should be prioritized for booster shots.
A second meta-analysis found that people with cirrhosis had higher COVID mortality.
More than half of individuals with post-COVID illness showed signs of MAFLD.
An extra booster dose raised antibody levels in one third of people with organ transplants, but many remain unprotected.
The early cancer is detected, the easier it is to treat.
Excess weight, which is often linked to metabolic abnormalities, can contribute to a wide variety of health problems.
People with both obesity and liver steatosis were at greater risk for hospitalization with COVID-19.
Twelve states have an adult obesity prevalence of 35% or more.
People with advanced liver cirrhosis are at greater risk for severe COVID-19 illness and death.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.